Nanrilkefusp alfa
- Generic Name
- Nanrilkefusp alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
Nanrilkefusp alfa is a human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity binding sushi+ domain of IL-15 receptor alpha (IL-15Ra).
- Associated Conditions
- -
- Associated Therapies
- -
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1
Terminated
- Conditions
- MelanomaThyroid CancerRenal Cell CarcinomaNon Small Cell Lung CancerSmall-cell Lung CancerBladder CancerMerkel Cell CarcinomaSkin Squamous Cell CarcinomaMicrosatellite Instability HighTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- SOTIO Biotech AG
- Target Recruit Count
- 115
- Registration Number
- NCT04234113
- Locations
- 🇫🇷
Institut Gustave Roussy, Paris, France
🇪🇸University Hospital Sanchinarro, Madrid, Spain
🇫🇷Hôpitaux Universitaires de Marseille Timone, Marseille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath